[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Companion Animal Pharmaceuticals Market by Indication (Infectious Diseases, Antibiotics, Parasiticides, Vaccines, Pain), Animal Type (Dogs, Cats, Horses), Distribution Channel (Veterinary Hospitals & Clinics), COVID-19 Impact - Global Forecast to 2026

April 2029 | 232 pages | ID: C583018D0F07EN
MarketsandMarkets

US$ 4,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The global companion animal pharmaceuticals market is projected to reach USD 18.5 billion by 2026 from USD 12.8 billion in 2021, at a CAGR of 7.6% during the forecast period. Companion animals play an important role in the lives of many, providing a sense of belonging and responsibility. Animal health products, especially pharmaceuticals, are the most widely used products for animal healthcare. They contribute significantly to the health and wellbeing of animals. Companion animal ownership and expenditure have witnessed a significant increase over the years. Pet owners are spending more per pet than ever before. The increasing number of people having pets, emphasis on animal healthcare and vaccination, increasing demand for animal healthcare products, increasing number of veterinary practitioners and their rising income levels in developed economies, increasing prevalence of zoonotic diseases, growth in companion animal adoption, increasing prevalence of animal diseases, and rising demand for pet insurance are some of the factors driving the growth of these markets. However, the limited number of new antibiotics, rising pet care costs, growing resistance to antimicrobials and antibiotics, and rising cost of vaccine storage are restraining the growth of this market to a certain extent.

“The dermatologic diseases segment to grow at the highest CAGR in the companion animal pharmaceuticals market, in the forecast period.”

Based on the prescription of pharmaceuticals for a number of disorders prevailing in animals, the companion animal pharmaceuticals market is segmented into infectious diseases, dermatologic diseases, orthopedic diseases, pain, behavioral disorders, and other indications. The dermatologic diseases segment is expected to grow at the highest CAGR during the forecast period. The increasing prevalence of arthritis, rising need for advanced orthopedic drugs, and growing pet population are some of the key factors driving the growth of this segment.

“The dogs segment holds the largest share in the animal type segment, in the forecast period.”

Based on animal type, the companion animal pharmaceuticals market is segmented into dogs, cats, horses, and other companion animals. The dogs segment accounted for the largest market share in 2020. The large share of this segment is attributed to the increasing dog population and rising ownership rate, increasing prevalence of zoonotic diseases and other skin allergies in dogs, rising canine healthcare expenditure, and the increasing number of pet insurers across the globe.

“Veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market by distribution channel segment in the forecast period”

Based on the distribution channel, the global companion animal pharmaceuticals market is segmented into veterinary hospitals, veterinary clinics, and retail pharmacies. The veterinary hospitals segment is expected to grow at the highest CAGR during the forecast period. The higher adoption of animal parasiticides and antibiotics in hospital settings, increasing incidence of infectious diseases, growing number of veterinary hospitals, growing ownership of companion animals, increasing veterinary expenditure, and growing awareness about animal health in developing countries, are some of the key factors driving the growth of this segment.

“North America holds the largest share in the companion animal pharmaceuticals market, by region, in the forecast period”

In 2020, North America accounted for the largest share of the companion animal pharmaceuticals market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the well-established base of animal health industries, the high adoption of companion animals, rising incidence of parasitic infections, the large number of hospitals and clinics, growing pool of veterinarians, and growing expenditure on animal health in the region. The growing number of research activities and funding and awareness campaigns in the field of veterinary health management is also expected to drive the growth of this market.

A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:
  • By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
  • By Designation: C-level–35%, Director Level–25%, and Others–40%
  • By Region: North America–45%, Europe–30%, Asia Pacific–20%, Latin America – 3%, Middle East & Africa–2%
The prominent players in the global companion animal pharmaceuticals market are Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Sant? Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK), Chanelle Pharma (Ireland), Kyoritsu Seiyaku (Japan), Zydus Animal Health and Investments Limited (India), Tianjin Ringpu Bio-Technology Co., Ltd. (China), HIPRA (Spain), Norbrook Holdings Limited (UK), Inovet (Belgium), Endovac Animal Health (US), ECO Animal Health Group plc (UK), Indian Immunologicals Ltd. (India), ALS Pvt. Ltd. (India), and Lutim Pharma Pvt. Ltd. (India).

Research Coverage:

The report analyzes the market for various companion animal pharmaceuticals and their adoption pattern. It aims at estimating the market size and future growth potential of the global companion animal pharmaceuticals market and different segments such as indication, animal type, distribution channels, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market
  • Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market.
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
  1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
  1.2.2 MARKETS COVERED
FIGURE 1 COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION
  1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.4 STAKEHOLDERS
1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
  2.1.1 SECONDARY RESEARCH
    2.1.1.1 Key data from secondary sources
  2.1.2 PRIMARY RESEARCH
    2.1.2.1 Primary sources
    2.1.2.2 Key data from primary sources
    2.1.2.3 Key industry insights
    2.1.2.4 Breakdown of primaries
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS
FIGURE 6 SUPPLY-SIDE ANALYSIS OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET
FIGURE 7 MARKET ANALYSIS APPROACH
FIGURE 8 US: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH
FIGURE 9 TOP-DOWN APPROACH
FIGURE 10 CAGR PROJECTIONS
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET (2021–2026): IMPACT ON MARKET GROWTH & CAGR
2.3 DATA TRIANGULATION APPROACH
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT/LIMITATIONS
2.7 COVID-19 HEALTH ASSESSMENT
2.8 COVID-19 ECONOMIC ASSESSMENT
2.9 ASSESSING THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 13 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 14 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY

FIGURE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2021 VS. 2026 (USD MILLION)
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET

4 PREMIUM INSIGHTS

4.1 COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW
FIGURE 19 RISING PET POPULATION TO DRIVE MARKET GROWTH
4.2 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2020)
FIGURE 20 INFECTIOUS DISEASES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE EUROPEAN MARKET IN 2020
4.3 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
4.4 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2019–2026)
FIGURE 22 NORTH AMERICA WILL CONTINUE TO DOMINATE THE COMPANION ANIMAL PHARMACEUTICALS MARKET DURING THE FORECAST PERIOD
4.5 COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 23 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
TABLE 2 COMPANION ANIMAL PHARMACEUTICALS MARKET: IMPACT ANALYSIS
  5.2.1 MARKET DRIVERS
    5.2.1.1 Growing prevalence of zoonotic diseases
TABLE 3 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013–2018)
    5.2.1.2 Rising demand for pet insurance with growing animal health expenditure
FIGURE 24 US: PET EXPENDITURE, 2010-2019 (USD BILLION)
FIGURE 25 US: PET HEALTH INSURANCE MARKET, 2014 VS. 2019 (USD MILLION)
    5.2.1.3 Growing investments by key players
    5.2.1.4 Initiatives by various government agencies and animal associations
    5.2.1.5 Growth in companion animal ownership rates
FIGURE 26 DEVELOPED COUNTRIES: PET POPULATION & PET OWNERSHIP
  5.2.2 MARKET RESTRAINTS
    5.2.2.1 Rising pet care costs
    5.2.2.2 Limited number of new product developments
    5.2.2.3 High storage cost of vaccines
  5.2.3 MARKET OPPORTUNITIES
    5.2.3.1 Lucrative growth opportunities in emerging markets
    5.2.3.2 Growing prevalence of animal diseases
    5.2.3.3 Technological advancements in manufacturing vaccines
  5.2.4 MARKET CHALLENGES
    5.2.4.1 Stringent regulatory approval process for drugs
    5.2.4.2 Inadequate surveillance and reporting systems of vaccines
    5.2.4.3 Diversity of parasite species

6 INDUSTRY INSIGHTS

6.1 INTRODUCTION
6.2 INDUSTRY TRENDS
  6.2.1 GROWING CONSOLIDATION IN THE ANIMAL HEALTHCARE INDUSTRY
TABLE 4 MAJOR ACQUISITIONS IN THE ANIMAL HEALTH INDUSTRY (2017–2019)
  6.2.2 INNOVATIONS IN ANIMAL HEALTHCARE PRODUCTS
TABLE 5 INNOVATIVE ANIMAL PHARMACEUTICAL TRENDS
6.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 PORTER’S FIVE FORCES ANALYSIS
  6.3.1 THREAT OF NEW ENTRANTS
  6.3.2 THREAT OF SUBSTITUTES
  6.3.3 BARGAINING POWER OF SUPPLIERS
  6.3.4 BARGAINING POWER OF BUYERS
  6.3.5 INTENSITY OF COMPETITIVE RIVALRY
6.4 REGULATORY ANALYSIS
FIGURE 27 DEVELOPMENT AND APPROVAL PROCESS FOR COMPANION ANIMAL PHARMACEUTICAL PRODUCTS
TABLE 7 US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS
FIGURE 28 EUROPE: COMPANION ANIMAL PHARMACEUTICAL PRODUCTS APPROVAL PROCESS
6.5 VALUE CHAIN ANALYSIS
FIGURE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS
6.6 SUPPLY CHAIN ANALYSIS
FIGURE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS
6.7 ECOSYSTEM ANALYSIS
  6.7.1 ECOSYSTEM ANALYSIS FOR THE COMPANION ANIMAL PHARMACEUTICALS MARKET
FIGURE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
6.8 IMPACT OF COVID-19 ON THE COMPANION ANIMAL PHARMACEUTICALS MARKET
6.9 PATENT ANALYSIS
  6.9.1 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS
FIGURE 32 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICAL PATENTS (2015–2020)
  6.9.2 TOP INVENTORS FOR COMPANION ANIMAL PHARMACEUTICALS
FIGURE 33 TOP INVENTORS FOR COMPANION ANIMAL PHARMACEUTICALS PATENTS (2015–2020)
  6.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS
FIGURE 34 TOP APPLICANT COUNTRIES FOR COMPANION ANIMAL PHARMACEUTICAL PATENTS (2015–2020)

7 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION

7.1 INTRODUCTION
TABLE 8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
7.2 INFECTIOUS DISEASES
TABLE 9 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 10 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
  7.2.1 PARASITICIDES
    7.2.1.1 Growing regulatory guidelines to prevent the spread of parasite-caused diseases is fueling the market growth
TABLE 11 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2019–2026 (USD MILLION)
  7.2.2 VACCINES
    7.2.2.1 Rising awareness among pet owners for vaccinating dogs and cats to drive market growth
TABLE 12 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD MILLION)
  7.2.3 ANTIBIOTICS AND ANTIMICROBIALS
    7.2.3.1 Antibiotics and antimicrobials help combat clinical and subclinical diseases in animals
TABLE 13 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2019–2026 (USD MILLION)
  7.2.4 OTHER COMPANION ANIMAL PHARMACEUTICALS
TABLE 14 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMAL PHARMACEUTICALS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 DERMATOLOGIC DISEASES
  7.3.1 GROWING CASES OF DERMATOLOGIC DISEASES HAVE INCREASED THE DEMAND FOR VETERINARY PHARMACEUTICALS
TABLE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 PAIN
  7.4.1 RISING PREVALENCE OF MUSCULOSKELETAL DISORDERS TO DRIVE SUPPORT MARKET GROWTH
TABLE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 ORTHOPEDIC DISEASES
  7.5.1 GROWING PREVALENCE OF OSTEOARTHRITIS AND THE INCREASING POPULATION OF OBESE PETS HAS INCREASED THE DEMAND FOR ORTHOPEDIC DRUGS
TABLE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.6 BEHAVIORAL DISORDERS
  7.6.1 GROWING AWARENESS AMONG PET OWNERS REGARDING BEHAVIORAL DISORDERS IS EXPECTED TO FUEL THE DEMAND FOR THESE DRUGS
TABLE 18 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
7.7 OTHER INDICATIONS
TABLE 19 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)

8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE

8.1 INTRODUCTION
TABLE 20 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
8.2 DOGS
  8.2.1 DOGS SEGMENT IS EXPECTED TO DOMINATE THE GLOBAL MARKET DURING THE FORECAST PERIOD
FIGURE 35 POPULATION OF PET DOGS IN INDIA (MILLION)
FIGURE 36 POPULATION OF PET DOGS GLOBALLY (MILLION)
TABLE 21 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 CATS
  8.3.1 GROWING RESEARCH ON FELINE HEALTH AND WELLBEING TO SUPPORT THE MARKET GROWTH
TABLE 22 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 HORSES
  8.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES IN THE EQUINE POPULATION TO DRIVE MARKET GROWTH
TABLE 23 HORSE POPULATION, BY REGION, 2016–2019 (MILLION)
TABLE 24 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 OTHER COMPANION ANIMALS
TABLE 25 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION)

9 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL

9.1 INTRODUCTION
TABLE 26 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
9.2 VETERINARY HOSPITALS
  9.2.1 VETERINARY HOSPITALS ARE THE LARGEST AND FASTEST-GROWING SEGMENT OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET
TABLE 27 VETERINARY VISIT EXPENSES FOR CATS AND DOGS IN THE US
TABLE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 VETERINARY CLINICS
  9.3.1 INCREASING NUMBER OF PRIVATE CLINICAL PRACTICES TO SUPPORT MARKET GROWTH
TABLE 29 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY, 2015 VS. 2019
TABLE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 RETAIL PHARMACIES
  9.4.1 EASY ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTION AND OTC TO SUPPORT THE MARKET GROWTH
TABLE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2019–2026 (USD MILLION)

10 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION

10.1 INTRODUCTION
TABLE 32 COMPANION ANIMAL POPULATION, BY COUNTRY, 2020 (THOUSAND)
FIGURE 37 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT
TABLE 33 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 38 EXPECTED GROWTH IN THE NUMBER OF VETERINARIANS IN NORTH AMERICA
FIGURE 39 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
TABLE 34 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 35 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 36 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 37 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 38 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.2.1 US
    10.2.1.1 The US dominates the North American companion animal pharmaceuticals market
FIGURE 40 US: INCREASE IN PET EXPENDITURE, 2010–2019 (USD BILLION)
TABLE 39 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2016 VS. 2018
TABLE 40 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 41 US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 42 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 43 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.2.2 CANADA
    10.2.2.1 Increasing pet adoption rate and rising animal health awareness to support market growth in Canada
TABLE 44 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 45 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 46 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 47 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 48 EUROPE: NUMBER OF VETERINARIANS, 2012–2018
TABLE 49 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 51 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 52 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 53 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.3.1 GERMANY
    10.3.1.1 Germany held the largest share of the European market in 2020
TABLE 54 GERMANY: COMPANION ANIMAL POPULATION, 2012–2018 (MILLION)
TABLE 55 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 56 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 57 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 58 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.3.2 UK
    10.3.2.1 Growing pet ownership rates to drive market growth
TABLE 59 UK: COMPANION ANIMAL POPULATION, 2010–2018 (MILLION)
TABLE 60 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 61 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 62 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 63 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.3.3 FRANCE
    10.3.3.1 Presence of major players in the country is expected to propel the companion animal pharmaceuticals market
TABLE 64 FRANCE: COMPANION ANIMAL POPULATION, 2010–2018 (MILLION)
TABLE 65 FRANCE: NUMBER OF VETERINARIANS, 2014 VS. 2016 VS. 2018
TABLE 66 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 67 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 69 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.3.4 SPAIN
    10.3.4.1 Increasing animal health expenditure is propelling market growth in Spain
TABLE 70 SPAIN: COMPANION ANIMAL POPULATION, 2014–2018 (MILLION)
TABLE 71 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 72 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 73 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 74 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.3.5 ITALY
    10.3.5.1 Growing animal healthcare expenditure to support market growth
TABLE 75 ITALY: COMPANION ANIMAL POPULATION, 2016–2018 (MILLION)
TABLE 76 ITALY: NUMBER OF VETERINARIANS, 2016 VS. 2019
TABLE 77 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 78 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 79 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 80 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.3.6 REST OF EUROPE
TABLE 81 ROE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION)
TABLE 82 COMPANION ANIMAL POPULATION IN THE REST OF EUROPE, 2019 (MILLION)
TABLE 83 ROE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2016 VS. 2019
TABLE 84 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 85 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 86 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 87 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 41 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
TABLE 88 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 89 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 90 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 91 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 92 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.4.1 CHINA
    10.4.1.1 China dominates the companion animal pharmaceuticals market
FIGURE 42 CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
TABLE 93 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 94 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 95 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 96 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.4.2 JAPAN
    10.4.2.1 Rising demand for imported breeds is driving pet adoption rates in the country
TABLE 97 JAPAN: NUMBER OF VETERINARIANS, 2016 VS. 2019
TABLE 98 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 99 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 100 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 101 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.4.3 INDIA
    10.4.3.1 India is an untapped market with large growth potential in companion animal pharmaceuticals
FIGURE 43 INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
TABLE 102 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 103 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 105 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.4.4 SOUTH KOREA
    10.4.4.1 Rising pet population and growing awareness about animal health to support market growth
TABLE 106 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 107 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 109 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
  10.4.5 REST OF ASIA PACIFIC
FIGURE 44 AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
TABLE 110 ROAPAC: NUMBER OF VETERINARIANS, 2012?2019
TABLE 111 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 112 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 113 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 114 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
  10.5.1 RISING POOL OF SKILLED VETERINARIANS AND GROWING PET HEALTH EXPENDITURE TO DRIVE THE MARKET GROWTH
TABLE 115 NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICAN COUNTRIES, 2016 VS. 2019
TABLE 116 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 117 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 118 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 119 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
  10.6.1 GROWING POPULATION OF COMPANION ANIMALS TO PROPEL MARKET GROWTH
TABLE 120 AFRICA: NUMBER OF VETERINARIANS, 2012 VS. 2017 VS. 2019
TABLE 121 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 122 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 123 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
TABLE 124 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY 2017 TO FEBRUARY 2021
11.3 GEOGRAPHICAL FOOTPRINT OF THE MAJOR PLAYERS IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET
FIGURE 45 GEOGRAPHIC REVENUE MIX: COMPANION ANIMAL PHARMACEUTICALS MARKET (2020)
11.4 COMPANY PRODUCT FOOTPRINT
FIGURE 46 PRODUCT PORTFOLIO ANALYSIS: COMPANION ANIMAL PHARMACEUTICALS MARKET
11.5 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS
FIGURE 47 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET (2015–2019)
11.6 MARKET SHARE ANALYSIS
FIGURE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2020
11.7 MARKET EVALUATION FRAMEWORK
FIGURE 49 MARKET EVALUATION FRAMEWORK: ACQUISITIONS—THE MOST WIDELY ADOPTED STRATEGY
11.8 COMPETITIVE LEADERSHIP MAPPING
  11.8.1 STARS
  11.8.2 EMERGING LEADERS
  11.8.3 PERVASIVE PLAYERS
  11.8.4 PARTICIPANTS
FIGURE 50 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
11.9 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS
  11.9.1 PROGRESSIVE COMPANIES
  11.9.2 DYNAMIC COMPANIES
  11.9.3 STARTING BLOCKS
  11.9.4 RESPONSIVE COMPANIES
FIGURE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020)
11.10 COMPETITIVE SITUATION AND TRENDS
  11.10.1 PRODUCT LAUNCHES & APPROVALS
TABLE 125 PRODUCT LAUNCHES & APPROVALS
  11.10.2 EXPANSIONS
TABLE 126 EXPANSIONS
  11.10.3 ACQUISITIONS
TABLE 127 ACQUISITIONS
  11.10.4 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
TABLE 128 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS

12 COMPANY PROFILES

12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, MnM View)*
  12.1.1 ZOETIS INC.
TABLE 129 ZOETIS INC.: BUSINESS OVERVIEW
FIGURE 52 ZOETIS: COMPANY SNAPSHOT (2020)
  12.1.2 MERCK & CO., INC.
TABLE 130 MERCK & CO., INC.: BUSINESS OVERVIEW
FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2020)
  12.1.3 BOEHRINGER INGELHEIM GMBH
TABLE 131 BOEHRINGER INGELHEIM GMBH: BUSINESS OVERVIEW
FIGURE 54 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2019)
  12.1.4 ELANCO ANIMAL HEALTH INCORPORATED
TABLE 132 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW
FIGURE 55 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2019)
  12.1.5 CEVA SANT? ANIMALE
TABLE 133 CEVA SANT? ANIMALE: BUSINESS OVERVIEW
  12.1.6 VIRBAC
TABLE 134 VIRBAC: BUSINESS OVERVIEW
FIGURE 56 VIRBAC: COMPANY SNAPSHOT (2019)
  12.1.7 VETOQUINOL S.A.
TABLE 135 VETOQUINOL S.A.: BUSINESS OVERVIEW
FIGURE 57 VETOQUINOL S.A.: COMPANY SNAPSHOT (2019)
  12.1.8 DECHRA PHARMACEUTICALS PLC
TABLE 136 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW
FIGURE 58 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2019)
  12.1.9 CHANELLE PHARMA
TABLE 137 CHANELLE PHARMA: BUSINESS OVERVIEW
  12.1.10 KYORITSU SEIYAKU
TABLE 138 KYORITSU SEIYAKU: BUSINESS OVERVIEW
  12.1.11 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED
TABLE 139 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED: BUSINESS OVERVIEW
FIGURE 59 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED: COMPANY SNAPSHOT (2019)
  12.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
TABLE 140 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
  12.1.13 HIPRA
TABLE 141 HIPRA: BUSINESS OVERVIEW
  12.1.14 NORBROOK HOLDINGS LIMITED
TABLE 142 NORBROOK HOLDINGS LIMITED: BUSINESS OVERVIEW
  12.1.15 INOVET
TABLE 143 INOVET: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
  12.2.1 ENDOVAC ANIMAL HEALTH
  12.2.2 ECO ANIMAL HEALTH GROUP PLC
  12.2.3 INDIAN IMMUNOLOGICALS LTD.
  12.2.4 ASHISH LIFE SCIENCE PVT. LTD.
  12.2.5 LUTIM PHARMA PVT. LTD.
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS


More Publications